Advaxis, Inc. (OTCBB ADXS) is a biotechnology company based upon the concept that in order to treat cancer and other diseases immunologically it is best to use a modified infectious micro-organism to elicit the most profound immune response possible, as this is what the immune system evolved to address. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of simultaneously stimulating every numerous aspects of the immune system simultaneously; thus coordinating innate, humoral (antibody), and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases. Unlike other therapeutic approaches, Advaxis’ Listeria technology has been able to constantly demonstrate complete therapeutic responses resulting in complete tumor regression, even in the presence of immune tolerance. The Company is the exclusive licensee of a broadly enabling platform technology for creating cancer vaccines and therapies for infectious diseases and other immune problems based upon genetically modified Listeria.
Web site: advaxis.com |
